SAN DIEGO--(BUSINESS WIRE)--Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced that Herb Boyer, PhD, co-founder of Genentech, will serve on the Banyan Biomarkers’ Board of Directors. Dr. Boyer co-founded Genentech in 1976 and served as a director of the company until its 2008 acquisition by Roche. He also was a vice president of the company from 1976 to 1990. Dr. Boyer also served on the board of Allergan for 19 years, 12 years as vice chairman and three years as chairman.
In addition, Dr. Boyer was a professor at the University of California, San Francisco and an investigator for the Howard Hughes Medical Institute. He is an elected member of the National Academy of Sciences and a fellow in the American Academy of Arts and Sciences. Dr. Boyer received the Albert Lasker Basic Medical Research Award in 1980 and the Shaw Prize for life science and medicine and the Albany Medical Center Prize in Medicine and Biomedical Research, each in 2004.
“Herb is a pioneer in the life sciences industry and we are privileged to welcome him to Banyan’s Board of Directors,” stated Hank Nordhoff, Banyan’s Chairman and CEO. “His experience in growing Genentech into the world’s finest biotech company will serve Banyan well as we look to become the world leader in diagnostic tests for the brain.”
Banyan Biomarkers is also announcing that Frédéric Sweeney, PhD, will also be joining the Banyan Biomarkers’ Board of Directors. Dr. Sweeney currently serves as Vice President, Business Development & Strategic Alliances at bioMérieux S.A., has held senior executive positions at T2 Biosystems, Inc., Tornado Spectral Systems Inc. and started his career as part for Canada’s largest life science venture capital and private equity firm. Dr. Sweeney received his PhD in Molecular and Medical Genetics from the University of Toronto as a Terry Fox Scholar.
“We are delighted to have Fred join our board during this pivotal time at Banyan,” said Mr. Nordhoff. “His knowledge, insight and years of diagnostics experience will be invaluable as we now scale the company and focus on the commercialization of our products.”
Mr. Nordhoff added, "On behalf of the Company and Board of Directors, I would also like to thank David Flagg for his extraordinary dedication and guidance in building Banyan into the diagnostics company that it is today. Because of his leadership, Banyan is positioned well to create long term value and improve the lives of patients suffering from brain injury.”
About Banyan Biomarkers
Banyan Biomarkers, Inc. is developing a blood test that could be used by physicians and healthcare providers to rapidly and objectively detect the presence of mild TBI, also known as concussions, and improve the medical management of head injured patients. The Company’s test uses two brain specific protein biomarkers (Banyan UCH-L1™ and Banyan GFAP™) that rapidly appear in the blood after a brain injury. To learn more about Banyan Biomarkers, visit www.banyanbio.com.